Top Banner
Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health
36

Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Dec 26, 2015

Download

Documents

Giles Butler
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Gilead -Topics in Human Pathophysiology

Fall 2010 Drug Safety and Public Health

Page 2: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Figure 8.7bFigure 8.7b

Page 3: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Systole – ventricles contract, semilunar valves open to allow blood to large arteries; AV valves close to prevent backflow to the atria

Diastole – ventricles relax, semilunar valves close to prevent backflow into the ventricles, AV valves open to allow ventricles to fill

Page 4: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

SA node is primary pacemaker AV node is secondary pacemaker AV bundle carries signal to ventricles Electrical signal stimulates muscle

contraction For the conduction system to work properly

adequate blood supply is required.

Page 5: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.
Page 6: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.
Page 7: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.
Page 8: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Coronary artery disease Myocardial ischemia Myocardial hypoxia Myocardial infarct Myocardial necrosis

Page 9: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

From wikipedia

Page 10: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Age

Male sex

Heredity

Smoking

Diabetes mellitus

Hypertension

High cholesterol

Obesity

Lack of exercise

Page 11: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Diagnosis◦ BP monitoring◦ Symptoms◦ ECG◦ Angiogram◦ Stress Test◦ Nuclear myocardial

perfusion tests

Page 12: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.
Page 13: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

For myocardial perfusion imaging (MPI) A2A adenosine receptor agonist Vasodilates coronary arteries as if exercising Injected into blood stream prior to gamma

camera scan Can give a good indication of myocardial

perfusion

Page 14: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

• Treatment– Coronary bypass

surgery– Angioplasty– Stents– Cholesterol lowering

agents– Anticoagulents– Antianginal

medications

Page 15: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

For angina Thought to inhibit a sodium ion

channel in the cardiac muscle cells Contraction of those cells might

normally cause compression of cardiac blood vessels during diastole.

Can be taken with other anti-anginal meds

Very effective

Page 16: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.
Page 17: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Congestive Heart Failure

• Heart becomes weak• Blood backs up in veins and capillaries• Fluid excess in tissues• Symptoms include shortness of breath,

edema, difficulty breathing (especially when lying down,) difficulty exercising

Page 18: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Congestive Heart Failure

• Causes: – cardiomyopathy– hypertension– lung disease– coronary artery disease– previous MI– valve disease

Page 19: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Blood Vessels and Pressure

• Artery structure and function• Control over smooth muscle• Vascular Disease

– Atherosclerosis– Pulmonary hypertension

Page 20: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.
Page 21: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Figure 8.10

Page 22: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Figure 8.1

Page 23: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Vessel Wall Structure

• Tunica intima – epithelium and connective tissue

• Tunica media – smooth muscle• Tunica externa– connective tissue and

epithelium

Page 24: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.
Page 25: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Arterial blood pressure and flow

• Systolic and diastolic pressure• Regulatory factors

– Cardiac – Sympathetic nervous system from vasomotor

center of brain stimulates smooth muscle– Chemical messengers – hormones, paracrines

Page 26: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Components of Orthe Nervous System

Figure 11.1

Organization of the Nervous System

Page 27: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Figure 11.12 (1 of 2)

Sympathetic and Parasympathetic Divisions of the Autonomic Nervous System

Page 28: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Figure 11.12 (2 of 2)

Sympathetic and Parasympathetic Divisions of the Autonomic Nervous System

Page 29: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Table 19.2

Hormonal Control of Blood Pressure

Page 30: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Pulmonary Arterial Hypertension (PAH)

• Pulmonary arteries become narrowed causing decreased gas exchange and difficulty breathing

• Causes R ventricular hypertrophy

• Blood will back up in veins

Page 31: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Pulmonary Hypertension

Page 32: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.
Page 33: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Common causes of PAH

Page 34: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Symptoms of PAH

• Chest pain, usually in the front of the chest• Dizziness• Fainting• Fatigue• Leg edema• Light-headedness during exercise• Shortness of breath during activity• Weakness

Page 35: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.
Page 36: Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.

Treatment for PAH• Letairis (ambrisentan)• Flolan or other prostacyclins• Bosentan (Tracleer)• Calcium channel blockers• Diuretics• Sildenafil (Viagra)• Supplemental oxygen• Surgical correction of defects• Lung transplant